Clinical trial · Interventional
FDG-PET Scan Response Guided Chemotherapy Strategy for Advanced Non-small Cell Lung Cancer
Standard Chemotherapy Strategy Versus Changing Chemotherapy Strategy as to FDG-PET Response After 1st Cycle of Standard Chemotherapy for Advanced Non-small Cell Lung Cancer
NCT01170923CI-TRIAL-00003724unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The usual response to chemotherapy is decided through the image change by computed tomography (CT), which is taken at least 6-9 weeks. In order to predict the response to chemotherapy earlier, patients received FDG-PET scan at the first cycle of chemotherapy. Chemotherapy was guided by the metabolic response by FDG-PET scan.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT | Device | — | UNRESOLVED |
| FDR-PET | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- FDG-PET guided
- description
- Chemotherapy regimen will be changed depending on metabolic response.
- interventionNames
- Device: FDR-PET
- type
- ACTIVE_COMPARATOR
- label
- CT guided
- description
- Chemotherapy regimen will be changed depending on CT findings (RECIST).
- interventionNames
- Device: CT
Primary outcomes (1)
- measure
- change in response rate
- timeFrame
- within 4 cycles
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed non-small cell carcinoma. 2. Stage IIIB (wet) or IV advanced NSCLC. 3. No evidence of prior malignancies for 3 years except treated basal cell or squamous cell carcinoma of skin and carcinoma in situ of uterine cervix. 4. Measurable disease by RECIST criteria. 5. Adequate organ function as follows. * Seum AST/ALT \< 2.5 x Upper normal limit (UNL) (if hepatic metastasis \< 5 x UNL) * Total bilirubin \< 1.5 x UNL * Serum creatinine \< 1.5 mg/dL * Absolute neutrophil count \> 1500/uL * Platelet \> 100,000/uL * Hemoglobin \> 9.0 g/dL 6. ECOG Performance status 0-1 7 Age \> 18 8\. If previously treated with major surgery, it should be over at least 4 weeks. And if previously treated with radiotherapy, it should be over at least 2 weeks. 9\. Written consent Exclusion Criteria: 1. Previous chemotherapy. 2. Symptomatic brain metastasis. 3. Concurrent severe medical illness. 4. Pregnancy and lactation. 5. If there are findings which may increase risk with chemotherapy or inhibit to analyze the result of clinical trial. * Uncontrolled diabetes mellitus.
References
Publications (0)
Data not yet available
No reference posted for this study.